This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Abbott (ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $107.93 in the latest trading session, marking a +0.33% move from the prior day.
Is Trending Stock Abbott Laboratories (ABT) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Abbott (ABT) Up 7.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Reasons to Retain Abbott (ABT) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Abbott (ABT) owing to the strength in its Diabetes business.
Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
The Zacks Analyst Blog Highlights Abbott Laboratories, ServiceNow, Schlumberger, Shopify and Workday
by Zacks Equity Research
Abbott Laboratories, ServiceNow, Schlumberger, Shopify and Workday are part of the Zacks top Analyst Blog.
Top Research Reports for Abbott Laboratories, ServiceNow & Schlumberger
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), ServiceNow, Inc. (NOW) and Schlumberger Limited (SLB).
Are Options Traders Betting on a Big Move in Abbott (ABT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Abbott (ABT) stock based on the movements in the options market lately.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Abbott's (ABT) Q3 Earnings Top Estimates, 2022 EPS View Up (Revised)
by Zacks Equity Research
Abbott's (ABT) Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Abbott's (ABT) Q2 Earnings Top Estimates, 2022 EPS View Up
by Zacks Equity Research
Abbott's (ABT) Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
U.S. Housing Starts Declined in September
by Zacks Equity Research
U.S. Housing Starts Declined in September
Pre-Markets Give Some Back; Housing Starts Lower; PG, ABT Beat
by Mark Vickery
The markets seem in a mood to give back some of the boon they've garnered over the past 3 of 4 sessions.
Abbott (ABT) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 26.37% and 8.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Apple, Abbott Laboratories, International Business Machines, Estee Lauder and Progressive
by Zacks Equity Research
Apple, Abbott Laboratories, International Business Machines, Estee Lauder and Progressive are included in this Analyst Blog.
Q3 Earnings Scorecard and Analyst Reports for Apple, Abbott, IBM & Others
by Sheraz Mian
Today's Research Daily features the Q3 earnings season scorecard and new research reports on Apple (AAPL), Abbott (ABT) and IBM (IBM) and others.
Abbott (ABT) Stock Moves -1.52%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $100.91, moving -1.52% from the previous trading session.
Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
What's in Store for Abbott Laboratories (ABT) in Q3 Earnings?
by Zacks Equity Research
Going by the industry-wide trend so far, logistical challenges and increasing unit costs might have weighed on the corporate profitability of Abbott (ABT) in Q3.
Why Abbott (ABT) Could Beat Earnings Estimates Again
by Zacks Equity Research
Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Analysts Estimate Abbott (ABT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
by Zacks Equity Research
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Abbott (ABT) Stock Moves -0.64%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $101.79, moving -0.64% from the previous trading session.